Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Preferred Dividend Payments (2016 - 2025)

Historic Preferred Dividend Payments for Guided Therapeutics (GTHP) over the last 13 years, with Q3 2025 value amounting to $43000.0.

  • Guided Therapeutics' Preferred Dividend Payments rose 1315.79% to $43000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $172000.0, marking a year-over-year decrease of 171.43%. This contributed to the annual value of $174000.0 for FY2024, which is 175.44% up from last year.
  • Guided Therapeutics' Preferred Dividend Payments amounted to $43000.0 in Q3 2025, which was up 1315.79% from $45000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Preferred Dividend Payments ranged from a high of $548000.0 in Q1 2022 and a low of -$55000.0 during Q1 2021
  • For the 5-year period, Guided Therapeutics' Preferred Dividend Payments averaged around $76315.8, with its median value being $48000.0 (2022).
  • In the last 5 years, Guided Therapeutics' Preferred Dividend Payments crashed by 55833.33% in 2021 and then soared by 109636.36% in 2022.
  • Over the past 5 years, Guided Therapeutics' Preferred Dividend Payments (Quarter) stood at $65000.0 in 2021, then dropped by 23.08% to $50000.0 in 2022, then decreased by 2.0% to $49000.0 in 2023, then fell by 2.04% to $48000.0 in 2024, then dropped by 10.42% to $43000.0 in 2025.
  • Its Preferred Dividend Payments stands at $43000.0 for Q3 2025, versus $45000.0 for Q2 2025 and $36000.0 for Q1 2025.